What is HC Wainwright's Forecast for CGEM Q1 Earnings?

Key Points

• HC Wainwright predicts Cullinan Therapeutics will report Q1 2026 earnings of ($1.05) per share, maintaining a "Buy" rating and a price target of $24.00.
• Recent earnings revealed a loss of ($1.07) per share, missing estimates of ($0.83) and underscoring the company's challenges in financial performance.
• Institutional investors have significantly increased their stakes in Cullinan Therapeutics, with major increases from firms like JPMorgan Chase and GAMMA Investing.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Cullinan Therapeutics in a report released on Thursday, August 21st. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.05) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q2 2026 earnings at ($1.08) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.24).

CGEM has been the subject of a number of other research reports. Morgan Stanley lowered their price target on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating for the company in a report on Monday, August 18th. UBS Group lowered their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating for the company in a report on Monday, May 12th. Finally, Stifel Nicolaus started coverage on shares of Cullinan Therapeutics in a report on Wednesday, June 11th. They issued a "buy" rating and a $22.00 price target for the company. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $26.80.

Cullinan Therapeutics Price Performance

Shares of CGEM stock traded up $0.23 during trading hours on Friday, hitting $7.87. 150,635 shares of the company's stock were exchanged, compared to its average volume of 418,622. The stock has a market cap of $464.70 million, a price-to-earnings ratio of -2.43 and a beta of -0.08. The stock's 50-day moving average is $7.76 and its 200-day moving average is $8.13. Cullinan Therapeutics has a 52 week low of $6.85 and a 52 week high of $19.89.

Institutional Investors Weigh In On Cullinan Therapeutics

Several hedge funds have recently bought and sold shares of CGEM. Boxer Capital Management LLC bought a new stake in shares of Cullinan Therapeutics during the fourth quarter worth $11,058,000. Orbimed Advisors LLC boosted its holdings in Cullinan Therapeutics by 81.5% during the fourth quarter. Orbimed Advisors LLC now owns 1,942,555 shares of the company's stock worth $23,660,000 after purchasing an additional 872,500 shares during the last quarter. Lynx1 Capital Management LP raised its position in Cullinan Therapeutics by 206.2% during the fourth quarter. Lynx1 Capital Management LP now owns 1,257,795 shares of the company's stock worth $15,320,000 after acquiring an additional 846,965 shares in the last quarter. Foresite Capital Management VI LLC bought a new stake in Cullinan Therapeutics during the fourth quarter worth $7,729,000. Finally, Blue Owl Capital Holdings LP raised its position in Cullinan Therapeutics by 17.9% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,370,972 shares of the company's stock worth $28,878,000 after acquiring an additional 360,000 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.